Roughly 6 to 12 percent of US women of reproductive age — between 5 and 6 million people — have PCOS, also known as polycystic ovary syndrome. Despite the name, PCOS is not really about cysts on the ovaries. It is a complex endocrine and metabolic syndrome characterized by irregular menstrual cycles, elevated androgens, and often insulin resistance. Many women with PCOS don’t have visible cysts at all, and many women with multiple ovarian follicles don’t have PCOS.
The condition is the most common cause of infertility in women, accounts for 70 to 80 percent of anovulatory infertility, and significantly raises the risk of type 2 diabetes, metabolic syndrome, and endometrial cancer if left unmanaged, according to the NIDDK. This guide explains the diagnostic criteria, the role of insulin resistance, and what treatment looks like depending on whether the priority is acne, fertility, weight, or long-term metabolic health.
What PCOS Actually Is
PCOS is a heterogeneous syndrome diagnosed clinically by the Rotterdam criteria: at least two of (1) irregular or absent ovulation, (2) clinical or biochemical hyperandrogenism, and (3) polycystic ovarian morphology on ultrasound. Other causes of similar symptoms — thyroid disease, hyperprolactinemia, congenital adrenal hyperplasia, Cushing’s syndrome — must be excluded first.
The polycystic appearance on ultrasound shows 12 or more follicles measuring 2 to 9 mm per ovary, or ovarian volume above 10 mL. These are not true cysts but immature follicles arrested in development. The pathophysiology centers on disordered LH and FSH ratios, ovarian androgen overproduction, and insulin resistance, which amplifies androgen production and reduces sex hormone binding globulin. For broader context on metabolic and endocrine conditions, see our guide to chronic conditions.
Symptoms
Menstrual irregularity is the most common presentation — cycles longer than 35 days or fewer than 8 cycles per year, including amenorrhea. Hyperandrogenism produces hirsutism (excess hair on face, chest, abdomen), acne (often jawline and chin), and androgenic alopecia (hair thinning at the crown). About half of patients are overweight or obese, with the visceral fat pattern that drives metabolic risk.
Other features include acanthosis nigricans (velvety dark patches in skin folds, marking insulin resistance), fatigue, mood disorders, sleep apnea, and infertility. Metabolic findings include impaired glucose tolerance in 30 to 40 percent and overt type 2 diabetes in 10 percent of women with PCOS by age 40.
Long-term, PCOS raises risk of endometrial hyperplasia and cancer (from chronic estrogen unopposed by progesterone), cardiovascular disease, NAFLD, and obstructive sleep apnea. Mental health is significantly affected — rates of depression, anxiety, and eating disorders are 2 to 3 times higher than in age-matched women without PCOS.
Diagnosis
Workup confirms the Rotterdam criteria and rules out mimics. Blood tests typically include total and free testosterone, DHEAS, 17-hydroxyprogesterone (to exclude congenital adrenal hyperplasia), TSH, prolactin, fasting glucose and insulin, A1c, and a lipid panel. Pelvic ultrasound is often deferred in adolescents because polycystic morphology is common in normal teens.
The 2023 international PCOS guidelines, summarized by the Endocrine Society, refined diagnostic thresholds and emphasized AMH as a possible alternative to ultrasound for ovarian morphology assessment in adults. They also explicitly recommend against making the diagnosis purely from a single ultrasound finding.
Treatment by Priority
PCOS treatment is symptom-driven. Different women need different things.
Menstrual regulation and androgen control
Combined oral contraceptives are first-line for cycle regulation, hirsutism, and acne. Most regimens lower androgens within 3 to 6 months. Spironolactone (50 to 200 mg/day) blocks androgen receptors and helps hirsutism and acne; it must be paired with reliable contraception because of teratogenicity. Topical eflornithine slows facial hair growth.
Insulin resistance and metabolic health
Metformin remains a cornerstone. It improves insulin sensitivity, reduces androgen levels modestly, and supports weight loss. Typical doses are 1,500 to 2,000 mg/day. GLP-1 receptor agonists (semaglutide, liraglutide) and tirzepatide are increasingly used off-label for PCOS-related obesity and insulin resistance, with average weight loss of 10 to 20 percent in early studies — substantially better than metformin alone.
Fertility
Letrozole is now first-line for ovulation induction in PCOS, replacing clomiphene based on the PPCOS II trial showing higher live birth rates. Live birth rates after 5 cycles of letrozole reach 27 to 30 percent. Metformin is sometimes added; gonadotropins and IVF follow if oral therapy fails. Modest weight loss (5 to 10 percent of body weight) restores ovulation in many patients independent of medication.
Diet and Lifestyle
Lifestyle modification is foundational. The 2023 international guidelines recommend any sustainable balanced diet pattern rather than promoting one specific diet. Mediterranean and lower-glycemic-load diets have the most evidence in PCOS for improving insulin resistance and androgen levels. Sustained 5 to 10 percent weight loss reliably improves cycle regularity, fertility, and metabolic markers.
Resistance training improves insulin sensitivity in PCOS more than aerobic exercise alone. Sleep is often overlooked — obstructive sleep apnea is 5 to 10 times more common in PCOS than in the general population and worsens insulin resistance independently. Many endocrinologists screen with home sleep studies in symptomatic patients.
When to seek emergency care: Call 911 or go to the nearest emergency room if you experience sudden severe pelvic pain (possible ovarian torsion or hemorrhagic cyst), heavy uterine bleeding with lightheadedness, severe shortness of breath or chest pain (possible pulmonary embolism, particularly on combined oral contraceptives), or signs of diabetic ketoacidosis with rapid breathing and altered mental status.
Long-Term Surveillance
PCOS requires ongoing monitoring. Most clinicians recheck glucose tolerance and lipids every 1 to 3 years, blood pressure annually, depression screening at every visit, and endometrial assessment in any woman with prolonged amenorrhea or abnormal uterine bleeding. Progestin-induced withdrawal bleeds (e.g., medroxyprogesterone 10 days every 1 to 3 months) protect the endometrium when contraception is not used.
Cardiovascular risk in PCOS is elevated but the full lifetime impact is still being characterized. According to Cleveland Clinic, current guidelines emphasize aggressive metabolic risk management starting in young adulthood rather than waiting for cardiovascular events.
When to See a Doctor
Cycles longer than 35 days or fewer than 8 per year, persistent acne or hirsutism, unexplained weight gain with insulin resistance signs, or difficulty conceiving for more than 6 to 12 months warrant gynecologic or endocrinologic evaluation. PCOS is often diagnosed in primary care, but complex management — fertility, refractory metabolic disease, ambiguous diagnosis — typically benefits from specialist input.
Frequently Asked Questions
Can I have PCOS without cysts on my ovaries?
Yes. Polycystic ovary syndrome can be diagnosed by Rotterdam criteria with just two of three features. Many patients have irregular cycles plus hyperandrogenism without polycystic ovaries on ultrasound. The name is misleading.
Will PCOS go away after menopause?
Cycle problems resolve with menopause by definition. Hyperandrogenism often improves but may persist. Metabolic risks — diabetes, cardiovascular disease, NAFLD — continue and require ongoing management. PCOS is a lifelong metabolic condition, not just a reproductive issue.
Is PCOS reversible with weight loss?
Significant weight loss markedly improves PCOS features in overweight and obese patients. Cycle regularity, fertility, and metabolic parameters often return to near-normal at 10 percent weight loss. Lean PCOS patients have a different phenotype where weight loss is less effective; treatment focuses on insulin sensitivity and androgen control.
Are GLP-1 medications safe for PCOS?
GLP-1 receptor agonists are not FDA-approved specifically for PCOS but are widely used off-label, particularly for obesity in PCOS. They are contraindicated in pregnancy and should be stopped before conception. Some patients with PCOS-related infertility ovulate during weight loss on GLP-1s, requiring contraception planning.
The Bottom Line
PCOS is best understood as a metabolic and endocrine syndrome that happens to affect the ovaries — not the other way around. Treatment matches the patient’s current priority: contraception and androgen control, fertility, weight, or long-term metabolic risk. The long-term goal is preventing diabetes, cardiovascular disease, and endometrial cancer, which means PCOS doesn’t end at the last fertility cycle. It needs lifelong attention.